Form D · Biotechnology
Tetherex Pharmaceuticals Corp
Oklahoma City, OK · CIK 0001634581
Offering snapshot reported Dec 16, 2020 · SEC filing
- Reported sold
- $0 Indefinite offering
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 3, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 16, 2020 | Initial | $0 | No comparison | 1 | SEC filing |
| Mar 6, 2018 | Initial | $42,980,475 | No comparison | 240 | SEC filing |
| Oct 9, 2015 | Amendment | $4,000,000 | $3,400,000vs Jun 17, 2015 | 30 | SEC filing |
| Jun 17, 2015 | Initial | $600,000 | No comparison | 2 | SEC filing |
| Feb 23, 2015 | Initial | $1,262,722 | No comparison | 14 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-383303
The shares were issued to the investor as partial consideration under a patent license agreement. Investor did not make a cash payment to the issuer for the shares, therefore there were no cash proceeds from which to determine the "Total Offering Amount."
Source: Form D, filed Dec 16, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Richard Alvarez | Executive |
| David Facloner | Executive |
| Todd Foley | Director |
| Philip Jones, M.D. | Director |
| David Keiser | Director |
| Rodger Mc Ever, M.D. | Director |
| Scott Rollins, Ph.D. | Director, Executive |
| Russell Rother | Executive |
| Russell Rother, Ph.D. | Director, Executive |
| Scott Samara | Director |
| Jonathan Stocker, Ph.D. | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
840 Research Parkway, Suite 516
Oklahoma City, OK, 73104
Oklahoma City, OK, 73104